Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

Company's belief that the supplemental data to be submitted in the amended NDA will overcome the need for additional trials, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drugs Advisory Committee that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for L- MTP-PE, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Ph
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Calif., April 4, 2011 MedeAnalytics announced today the ... proposed rule for the Medicare Shared Savings Program issued ... March 31, 2011. (Logo:   http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ... Summary and Analysis of the Proposed Rule," covers a ...
... reveals a potentially highly effective treatment for heterotopic ossification ... bone tissue. HO comes in two main forms—one that ... wounded military personnel and surgery patients and is triggered ... animal study by developmental biologists shows that a drug ...
... SAN DIEGO, April 1, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... 2011 the Compensation Committee of its Board of Directors approved ... of 258,000 shares of common stock to 7 new employees. ... option has an exercise price per share equal to $11.83, ...
Cached Biology Technology:ACO Proposed Rule Simplified: MedeAnalytics Releases Comprehensive White Paper 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 3Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 4Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2
(Date:4/17/2014)... is the process whereby the genetic information of ... as proteins, which have numerous different functions in ... important intermediary during gene expression, by relating the ... involved in manufacturing proteins. , By examining ... present in an organism at a given time, ...
(Date:4/17/2014)... Scientists have uncovered a new way the immune system ... aid efforts to use immune cells to treat illness. ... have the immunological equivalent of "neighborhood police" specialized ... single organ, instead of an entire city, the body. ... St. Louis have shown that the liver, skin and ...
(Date:4/17/2014)... derive from Charles Darwin, whose ideas in turn ... the 19th century, a period when landowners vigorously ... from Darwin that we inherit the ideas that ... species and total human control over breeding and ... industrial setting has been applied too broadly in ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4
... time that embryonic stem (ES) cells cultured in the ... viable offspring. The research, published in the July issue ... studies, including investigation of mechanisms involved in sperm production ... Previous studies have shown that ES cells grown in ...
... San Diego have developed what they call a "Smart ... new drugs for toxic interactions or identify cells in ... blood. , Their invention, described in the June 20 ... the American Chemical Society, uses porous silicon crystals filled ...
... lend new insight into the mechanism of genomic imprinting, ... in the silencing of an imprinted gene cluster in ... gene based upon which parent it has been inherited ... human disorders, Prader-Willi and Angelman syndromes, result from the ...
Cached Biology News:Sperm created in the laboratory from embryonic stem cells produce viable progeny 2UCSD researchers develop 'smart petri dish' 2UCSD researchers develop 'smart petri dish' 3
...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: